Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant
Part of paid clinical trials in Madison, Wisconsin.
- Sponsor
- University of Wisconsin, Madison
- Study ID
- NCT00167791
- Status
- Withdrawn
Conditions
- End Stage Renal Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- rituximab — DRUGRituximab 375mg/m2 IV weekly times 4 weeks
Study Details
This is a study of patients who have a high risk of kidney rejection before kidney transplant. The hypothesis is that treatment with a medication called rituximab will make it possible for them to receive a kidney transplant from a donor who previously did not present a good match.
Key Dates
- Start date
- Jul 31, 2005
- Status verified
- Apr 2014
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Conversion of a positive donor specific cross-match to a living donor to a negative cross-match thereby allowing successful transplantation. [ Time Frame: assess 4 weeks after Rituximab treatment completed ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Wisconsin | Madison | Wisconsin | 53792 | - |
Find similar trials in Madison, WI
By research site
Related Studies
- Partners Calciphylaxis BiobankRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic ProfilePHASE2/PHASE3 · Recruiting · Roberto Gedaly · Lexington, Kentucky
- Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ DonorsRecruiting · Johns Hopkins University · San Diego, California
- Blood Pressure Slopes and Ultrafiltration in Hemodialysis PatientsRecruiting · VA Office of Research and Development · Dallas, Texas